Effect of circ72309 overexpression on gene expression related to gemcitabine sensitivity in pancreatic cancer cell lines

Understanding the molecular characteristics of gemcitabine sensitivity in pancreatic cancer is essential for advancing individualized treatment strategies. This study identifies circ72309 as a potential contributor to improve gemcitabine sensitivity. circ72309 decreased cytidine deaminase, a nucleoside enzyme which transforms gemcitabine into an inactive form, via reactive oxygen species activity, and increased solute carrier family 29 member 1 (SLC29A1), a nucleoside transporter which imports gemcitabine into cells, by regulating targeted miRNAs. Overall design: To identify the changes of mRNA expression, gemcitabine-resistance pancreatic cancer cell line (GR3) was established and transfected with either circ72309 vector or negative control (scramble) oligonucleotides. Gene expression profiling was performed using RNA-seq data obtained from these two cell lines. A comparative analysis of the RNA-seq data was conducted to evaluate gene expression profiles between circ72309-transfected cells and scramble controls.